PURPOSE: Children younger than 24 months with small (< 550 g), favorable histology (FH) Wilms tumors (WTs) were shown in a pilot study to have an excellent prognosis when treated with nephrectomy only. PATIENTS AND METHODS: A study of nephrectomy only for the treatment of selected children with FH WT was undertaken. Stringent stopping rules were designed to insure closure of the study if the true 2-year relapse-free survival rate was 90% or lower. RESULTS: Seventy-five previously untreated children younger than 24 months with stage I/FH WTs for which the surgical specimen weighed less than 550 g were treated with nephrectomy only. Three patients developed metachronous, contralateral WT 1.1, 1.4, and 2.3 years after nephrectomy, and eight patients relapsed 0.3 to 1.05 years after diagnosis (median, 0.4 years; mean, 0.51 years). The sites of relapse were lung (n = 5) and operative bed (n = 3). The 2-year disease-free (relapse and metachronous contralateral WT) survival rate was 86.5%. The 2-year survival rate is 100% with a median follow-up of 2.84 years. The 2-year disease-free survival rate (excluding metachronous contralateral WT) was 89.2%, and the 2-year cumulative risk of metachronous contralateral WT was 3.1%. CONCLUSION: Children younger than 24 months treated with nephrectomy only for a stage I/FH WT that weighed less than 550 g had a risk of relapse, including the development of metachronous contralateral WT, of 13.5% 2 years after diagnosis. All patients who experienced relapse on this trial are alive at this time. This approach will be re-evaluated in a clinical trial using a less conservative stopping rule.
PURPOSE:Children younger than 24 months with small (< 550 g), favorable histology (FH) Wilms tumors (WTs) were shown in a pilot study to have an excellent prognosis when treated with nephrectomy only. PATIENTS AND METHODS: A study of nephrectomy only for the treatment of selected children with FH WT was undertaken. Stringent stopping rules were designed to insure closure of the study if the true 2-year relapse-free survival rate was 90% or lower. RESULTS: Seventy-five previously untreated children younger than 24 months with stage I/FH WTs for which the surgical specimen weighed less than 550 g were treated with nephrectomy only. Three patients developed metachronous, contralateral WT 1.1, 1.4, and 2.3 years after nephrectomy, and eight patients relapsed 0.3 to 1.05 years after diagnosis (median, 0.4 years; mean, 0.51 years). The sites of relapse were lung (n = 5) and operative bed (n = 3). The 2-year disease-free (relapse and metachronous contralateral WT) survival rate was 86.5%. The 2-year survival rate is 100% with a median follow-up of 2.84 years. The 2-year disease-free survival rate (excluding metachronous contralateral WT) was 89.2%, and the 2-year cumulative risk of metachronous contralateral WT was 3.1%. CONCLUSION:Children younger than 24 months treated with nephrectomy only for a stage I/FH WT that weighed less than 550 g had a risk of relapse, including the development of metachronous contralateral WT, of 13.5% 2 years after diagnosis. All patients who experienced relapse on this trial are alive at this time. This approach will be re-evaluated in a clinical trial using a less conservative stopping rule.
Authors: Conrad V Fernandez; Ning Li; Elizabeth A Mullen; Paul E Grundy; Elizabeth J Perman; Robert C Shamberger; Peter F Ehrlich; Jeffrey S Dome Journal: J Pediatr Hematol Oncol Date: 2011-10 Impact factor: 1.289
Authors: Elizabeth J Perlman; Paul E Grundy; James R Anderson; Lawrence J Jennings; Daniel M Green; Jeffrey S Dome; Robert C Shamberger; E Cristy Ruteshouser; Vicki Huff Journal: J Clin Oncol Date: 2010-12-28 Impact factor: 44.544
Authors: M Hassan Alkazemi; Zachary R Dionise; Ruiyang Jiang; Steven Wolf; Gina-Maria Pomann; Elisabeth T Tracy; Henry E Rice; Jonathan C Routh Journal: J Pediatr Surg Date: 2019-05-31 Impact factor: 2.545
Authors: Conrad V Fernandez; Elizabeth J Perlman; Elizabeth A Mullen; Yueh-Yun Chi; Thomas E Hamilton; Kenneth W Gow; Fernando A Ferrer; Douglas C Barnhart; Peter F Ehrlich; Geetika Khanna; John A Kalapurakal; Tina Bocking; Vicky Huff; Jing Tian; James I Geller; Paul E Grundy; James R Anderson; Jeffrey S Dome; Robert C Shamberger Journal: Ann Surg Date: 2017-04 Impact factor: 12.969
Authors: Peter F Ehrlich; James R Anderson; Michael L Ritchey; Jeffrey S Dome; Daniel M Green; Paul E Grundy; Elizabeth J Perlman; John A Kalapurakal; Norman E Breslow; Robert C Shamberger Journal: J Clin Oncol Date: 2013-02-04 Impact factor: 44.544
Authors: Jeffrey S Dome; Conrad V Fernandez; Elizabeth A Mullen; John A Kalapurakal; James I Geller; Vicki Huff; Eric J Gratias; David B Dix; Peter F Ehrlich; Geetika Khanna; Marcio H Malogolowkin; James R Anderson; Arlene Naranjo; Elizabeth J Perlman Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Simone T Sredni; Samantha Gadd; Chiang-Ching Huang; Norman Breslow; Paul Grundy; Daniel M Green; Jeffrey S Dome; Robert C Shamberger; J Bruce Beckwith; Elizabeth J Perlman Journal: Clin Cancer Res Date: 2009-11-10 Impact factor: 12.531
Authors: Hemant B Tongaonkar; Sajid S Qureshi; Purna A Kurkure; Mary-Ann A Muckaden; Brijesh Arora; Thyavihalli B Yuvaraja Journal: Indian J Urol Date: 2007-10